1150 related articles for article (PubMed ID: 15998903)
1. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G;
J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903
[TBL] [Abstract][Full Text] [Related]
2. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
Cataliotti L; Buzdar AU; Noguchi S; Bines J; Takatsuka Y; Petrakova K; Dube P; de Oliveira CT
Cancer; 2006 May; 106(10):2095-103. PubMed ID: 16598749
[TBL] [Abstract][Full Text] [Related]
3. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
Dowsett M; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; Smith IE
J Clin Oncol; 2005 Apr; 23(11):2477-92. PubMed ID: 15767642
[TBL] [Abstract][Full Text] [Related]
4. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
5. The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
Banerjee S; Pancholi S; A'hern R; Ghazoui Z; Smith IE; Dowsett M; Martin LA
Clin Cancer Res; 2008 May; 14(9):2656-63. PubMed ID: 18451229
[TBL] [Abstract][Full Text] [Related]
6. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study.
Dixon JM; Renshaw L; Bellamy C; Stuart M; Hoctin-Boes G; Miller WR
Clin Cancer Res; 2000 Jun; 6(6):2229-35. PubMed ID: 10873072
[TBL] [Abstract][Full Text] [Related]
7. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
8. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.
Dowsett M; Cuzick J; Howell A; Jackson I;
Br J Cancer; 2001 Aug; 85(3):317-24. PubMed ID: 11487258
[TBL] [Abstract][Full Text] [Related]
10. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G;
Clin Cancer Res; 2005 Jan; 11(2 Pt 2):951s-8s. PubMed ID: 15701892
[TBL] [Abstract][Full Text] [Related]
11. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A
Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
[TBL] [Abstract][Full Text] [Related]
12. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Cuzick J; Coibion M; Bianco AR
BJOG; 2003 Dec; 110(12):1099-106. PubMed ID: 14664881
[TBL] [Abstract][Full Text] [Related]
13. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
14. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
Cella D; Fallowfield L; Barker P; Cuzick J; Locker G; Howell A;
Breast Cancer Res Treat; 2006 Dec; 100(3):273-84. PubMed ID: 16944295
[TBL] [Abstract][Full Text] [Related]
15. Focus on anastrozole and breast cancer.
Mokbel K
Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
[TBL] [Abstract][Full Text] [Related]
16. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
Kaufmann M; Jonat W; Hilfrich J; Eidtmann H; Gademann G; Zuna I; von Minckwitz G
J Clin Oncol; 2007 Jul; 25(19):2664-70. PubMed ID: 17563395
[TBL] [Abstract][Full Text] [Related]
17. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
Buzdar AU; Jones SE; Vogel CL; Wolter J; Plourde P; Webster A
Cancer; 1997 Feb; 79(4):730-9. PubMed ID: 9024711
[TBL] [Abstract][Full Text] [Related]
18. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Dowsett M; Allred C; Knox J; Quinn E; Salter J; Wale C; Cuzick J; Houghton J; Williams N; Mallon E; Bishop H; Ellis I; Larsimont D; Sasano H; Carder P; Cussac AL; Knox F; Speirs V; Forbes J; Buzdar A
J Clin Oncol; 2008 Mar; 26(7):1059-65. PubMed ID: 18227529
[TBL] [Abstract][Full Text] [Related]
19. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
Fallowfield L; Cella D; Cuzick J; Francis S; Locker G; Howell A
J Clin Oncol; 2004 Nov; 22(21):4261-71. PubMed ID: 15514369
[TBL] [Abstract][Full Text] [Related]
20. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
Buzdar AU
Expert Rev Anticancer Ther; 2002 Dec; 2(6):623-9. PubMed ID: 12503208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]